Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

222
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
222
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

171
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
171
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

489
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
489
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

357
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
357
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

217
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
217
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

154
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
154

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimizing trial design for evaluating combination therapies in IBD.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Anti-fibrotic therapy in Crohn's disease: hype or reality-can intestinal fibrosis be targeted effectively?

Expert review of gastroenterology & hepatology·2026
Same author

[Updated S3 guideline on ulcerative colitis].

Zeitschrift fur Gastroenterologie·2026
Same author

[Version 7.0 of the S3 Guideline on Ulcerative Colitis sets out clearly defined treatment goals, an open treatment sequence, and a call for improved cross-sectoral care].

Zeitschrift fur Gastroenterologie·2026
Same author

Obefazimod (ABX464) for moderate-to-severe Crohn's disease: clinical development of a novel oral therapeutic approach.

Expert opinion on emerging drugs·2026
Same author

Patient-Reported Outcomes in Clinical Trials of Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026

Related Experiment Video

Updated: Jul 23, 2025

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:21

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

187

Bowel Urgency in Ulcerative Colitis: Current Perspectives and Future Directions.

Marla Dubinsky1, Alison Potts Bleakman2, Remo Panaccione3

  • 1Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center, Icahn School of Medicine at Mount Sinai, Icahn School of Medicine, New York, New York, USA.

The American Journal of Gastroenterology
|July 12, 2023
PubMed
Summary

Bowel urgency (BU) significantly impacts ulcerative colitis (UC) patients, affecting quality of life and treatment satisfaction. Better assessment tools and management strategies are needed to address this disruptive symptom.

More Related Videos

Performing Colonoscopic-Guided Pinch Biopsies in Mice and Evaluating Subsequent Tissue Changes
08:52

Performing Colonoscopic-Guided Pinch Biopsies in Mice and Evaluating Subsequent Tissue Changes

Published on: February 5, 2021

4.5K
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.3K

Related Experiment Videos

Last Updated: Jul 23, 2025

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:21

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

187
Performing Colonoscopic-Guided Pinch Biopsies in Mice and Evaluating Subsequent Tissue Changes
08:52

Performing Colonoscopic-Guided Pinch Biopsies in Mice and Evaluating Subsequent Tissue Changes

Published on: February 5, 2021

4.5K
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.3K

Area of Science:

  • Gastroenterology
  • Clinical Medicine
  • Patient-Reported Outcomes

Background:

  • Bowel urgency (BU) is a prevalent and disruptive symptom in ulcerative colitis (UC).
  • BU negatively impacts patients' quality of life and psychosocial functioning.
  • It is a key driver of treatment dissatisfaction and a priority for symptom improvement in UC patients.

Approach:

  • This review examines the pathophysiology of BU in UC, including rectal inflammation, hypersensitivity, and reduced compliance.
  • It highlights the clinical importance of BU and its impact on patient well-being.
  • The review discusses patient-reported outcome measures (PROMs) for assessing BU severity.

Key Points:

  • Patients often underreport BU due to embarrassment, and healthcare providers may lack awareness or tools for assessment.
  • Effective management of BU requires validated PROMs for clinical trials and practice.
  • Understanding BU's multifactorial mechanisms is crucial for developing targeted therapies.

Conclusions:

  • There is a need for responsive and reliable PROMs to evaluate BU treatments in UC.
  • Improved awareness and assessment of BU are essential for better UC management.
  • Future UC management strategies should prioritize addressing bowel urgency.